Next-generation immune checkpoint inhibitors as promising functional molecules in cancer therapeutics
Open Access
- 20 September 2023
- journal article
- editorial
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 42 (3) , 597-600
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- T cells specific for α-myosin drive immunotherapy-related myocarditisNature, 2022
- Molecular imaging of immune checkpoints in oncology: Current and future applicationsCancer Letters, 2022
- Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapySeminars in Cancer Biology, 2022
- Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directionsSeminars in Cancer Biology, 2022
- A topography of immunotherapies against gastrointestinal malignanciesPanminerva Medica, 2022
- Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignanciesJournal for ImmunoTherapy of Cancer, 2022
- Immune checkpoint signaling and cancer immunotherapyCell Research, 2020
- Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanismsImmunology, 2019